MX2014001966A - Inhibidores de la amida de acidos grasos (faah) restringidos perifericamente por bifenil metasustituido. - Google Patents

Inhibidores de la amida de acidos grasos (faah) restringidos perifericamente por bifenil metasustituido.

Info

Publication number
MX2014001966A
MX2014001966A MX2014001966A MX2014001966A MX2014001966A MX 2014001966 A MX2014001966 A MX 2014001966A MX 2014001966 A MX2014001966 A MX 2014001966A MX 2014001966 A MX2014001966 A MX 2014001966A MX 2014001966 A MX2014001966 A MX 2014001966A
Authority
MX
Mexico
Prior art keywords
faah
methods
present
meta
peripherally restricted
Prior art date
Application number
MX2014001966A
Other languages
English (en)
Other versions
MX354772B (es
Inventor
Daniele Piomelli
Guillermo Moreno-Sanz
Tiziano Bandiera
Marco Mor
Giorgio Tarzia
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2014001966A publication Critical patent/MX2014001966A/es
Publication of MX354772B publication Critical patent/MX354772B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona métodos para realizar y utilizar inhibidores restringidos periféricamente de la hidrolasa de la amida de ácidos grasos (FAAH). La presente invención proporciona compuestos y composiciones que suprimen la actividad de la FAAH y aumenta los niveles de anandamida fuerza del sistema nervioso central (SNC). La presente invención también establece métodos para inhibir la FAAH, así como métodos para tratar afecciones tales como, de modo no taxativo, dolor inflmación, trastornos inmunológicos, dermatitis, mucositis, la hiperreactividad de neuronas sensoriales periféricas, neurodermatitis y vejiga hiperactiva. Por consiguiente, la invención también proporciona compuestos, métodos y composiciones farmacéuticas para tratar afecciones en las que la inhibición selectiva de la FAAH periférica (en oposición a la FAAH del SNC) sería beneficiosa.
MX2014001966A 2011-08-19 2012-08-17 Inhibidores de la amida de acidos grasos (faah) restringidos perifericamente por bifenil metasustituido. MX354772B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161525636P 2011-08-19 2011-08-19
PCT/US2012/051478 WO2013028570A2 (en) 2011-08-19 2012-08-17 Meta-substituted biphenyl peripherally restricted faah inhibitors

Publications (2)

Publication Number Publication Date
MX2014001966A true MX2014001966A (es) 2015-04-08
MX354772B MX354772B (es) 2018-03-21

Family

ID=47747054

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001966A MX354772B (es) 2011-08-19 2012-08-17 Inhibidores de la amida de acidos grasos (faah) restringidos perifericamente por bifenil metasustituido.

Country Status (12)

Country Link
US (1) US9745255B2 (es)
EP (1) EP2744778B1 (es)
JP (1) JP6092870B2 (es)
KR (1) KR102079404B1 (es)
CN (1) CN104203906B (es)
AU (1) AU2012299060B2 (es)
BR (1) BR112014003886B1 (es)
CA (1) CA2844812C (es)
DK (1) DK2744778T3 (es)
ES (1) ES2708723T3 (es)
MX (1) MX354772B (es)
WO (1) WO2013028570A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100485727B1 (ko) * 2004-06-24 2005-04-27 주식회사 바이오리더스 폴리감마글루탐산-비타민 복합체 및 그 용도
KR102079404B1 (ko) 2011-08-19 2020-02-19 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 메타-치환된 비페닐 말초 제한형 faah 억제제
WO2014023325A1 (en) * 2012-08-06 2014-02-13 Fondazione Istituto Italiano Di Tecnologia Multitarget faah and cox inhibitors and therapeutical uses thereof
ES2908240T3 (es) 2014-04-07 2022-04-28 Univ California Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
EP3334416A1 (en) * 2015-08-11 2018-06-20 Eyesiu Medicines B.V. Pegylated lipid nanoparticle with bioactive lipophilic compound
ES2910787T3 (es) * 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y métodos de tratamiento con los mismos
PH12018000077B1 (en) 2017-07-05 2021-07-09 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US10702487B2 (en) 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity
PH12018000227A1 (en) 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
GB201802326D0 (en) 2018-02-13 2018-03-28 Ucl Business Plc Gene therapy
EP3762034B1 (en) 2018-03-05 2025-08-27 Wylder Nation Foundation A fatty acid amide hydrolase (faahi) inhibitor for use in inhibiting the cellular accumulation of a sphingolipid in a subject that has lysosomal storage disease or disorder
SG11202107213WA (en) * 2019-01-10 2021-07-29 Travecta Therapeutics Pte Ltd Anandamide compounds
WO2022020756A1 (en) * 2020-07-23 2022-01-27 John Mansell Compositions and methods for treating pain and anxiety disorders
CN120965462B (zh) * 2025-10-17 2026-02-17 四川奥邦古得药业有限公司 用于生产3,5-二醚戊苯的方法及其在制备3,5-二羟基戊苯中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4325889A (en) 1978-08-04 1982-04-20 Bayer Aktiengesellschaft Process for the preparation of 1-amino-8-naphthol-3,6-disulphonic acid (H-acid)
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
DE69314148T2 (de) 1992-12-17 1998-01-15 Valeo Systemes Essuyage Stromversorgungsverfahren und -vorrichtung für einen elektrischen Motor zum Antrieb eines Scheibenwischers eines Kraftfahrzeugs
US5576220A (en) 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
CA2206192A1 (en) 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
EP0942730A1 (en) 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating bipolar disorders
GB9701453D0 (en) 1997-01-24 1997-03-12 Leo Pharm Prod Ltd Aminobenzophenones
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
RU2198873C2 (ru) 1998-02-26 2003-02-20 Акцо Нобель Н.В. Производные азетидина и пирролидина
US6348498B1 (en) 1998-05-29 2002-02-19 Neurosciences Research Foundation, Inc. Control of pain with endogenous cannabinoids
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US20030134894A1 (en) 1999-04-07 2003-07-17 Daniele Piomelli Methods of treating mental diseases, inflammation and pain
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
WO2003097573A1 (en) 2002-05-16 2003-11-27 Sepracor, Inc. Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
FR2842808B1 (fr) 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
EA010267B1 (ru) * 2002-10-07 2008-06-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Модуляция тревоги через блокаду гидролиза анандамида
FR2850377B1 (fr) 2003-01-23 2009-02-20 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) 2004-02-26 2006-05-05 Sanofi Synthelabo Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
US20070155707A1 (en) 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
WO2008067196A2 (en) 2006-11-16 2008-06-05 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
CA2674359A1 (en) * 2006-11-20 2008-05-29 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
TW200948805A (en) 2008-03-07 2009-12-01 Sigma Tau Ind Farmaceuti Enol carbamate derivatives as modulators of fatty acid amide hydrolase
WO2011046954A1 (en) 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
US9187413B2 (en) 2010-07-28 2015-11-17 The Regents Of The University Of California Peripherally restricted FAAH inhibitors
WO2012167133A2 (en) 2011-06-01 2012-12-06 The Regents Of The University Of California Inhibitors of anandamide transport and their therapeutic uses
KR102079404B1 (ko) 2011-08-19 2020-02-19 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 메타-치환된 비페닐 말초 제한형 faah 억제제
ES2908240T3 (es) 2014-04-07 2022-04-28 Univ California Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos

Also Published As

Publication number Publication date
BR112014003886A8 (pt) 2018-01-23
JP6092870B2 (ja) 2017-03-08
BR112014003886B1 (pt) 2022-04-19
DK2744778T3 (en) 2019-03-04
WO2013028570A3 (en) 2013-04-18
AU2012299060A1 (en) 2014-04-03
EP2744778A4 (en) 2015-04-08
MX354772B (es) 2018-03-21
CN104203906A (zh) 2014-12-10
CN104203906B (zh) 2018-03-13
NZ622480A (en) 2016-05-27
WO2013028570A2 (en) 2013-02-28
HK1198644A1 (en) 2015-05-22
EP2744778B1 (en) 2019-01-16
EP2744778A2 (en) 2014-06-25
ES2708723T3 (es) 2019-04-10
JP2014527532A (ja) 2014-10-16
KR102079404B1 (ko) 2020-02-19
CA2844812A1 (en) 2013-02-28
AU2012299060B2 (en) 2017-06-01
KR20150100485A (ko) 2015-09-02
US20140288170A1 (en) 2014-09-25
BR112014003886A2 (pt) 2017-03-21
US9745255B2 (en) 2017-08-29
CA2844812C (en) 2019-10-22

Similar Documents

Publication Publication Date Title
MX354772B (es) Inhibidores de la amida de acidos grasos (faah) restringidos perifericamente por bifenil metasustituido.
EA033374B9 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
MX367341B (es) Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
MY171091A (en) Inhibitors of b-secretase
IN2014DN08025A (es)
PH12015500832A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
MX2013005549A (es) Aminas heterociclicas y sus usos.
MX2013006598A (es) Inhibidores de la amida hidrolasa de acidos grasos (faah).
EA201391332A1 (ru) Лиганды опиоидных рецепторов и способы их применения и получения
WO2012015758A3 (en) Methods of treating pain
MD20150071A2 (ro) Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
WO2015011284A3 (en) Inhibitors of fapp2 and uses thereof
WO2013119946A8 (en) Long chain base sphingosine kinase inhibitors
MX348024B (es) Compuestos de adamantilo.
PH12016501159A1 (en) Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system
TN2015000032A1 (en) Inhibitors of beta-secretase
WO2012145737A8 (en) Fatty acid amide hydrolase inhibitors for treating pain
MX2011012140A (es) Ranolazina para el tratamiento de problemas del snc.
WO2011153377A3 (en) Methods and compositions for treating a subject for central nervous system (cns) injury
IN2014DN11027A (es)
WO2014144836A3 (en) Carbamate derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors
WO2012174552A3 (en) Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system
GEAP201813784A (en) Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it
EP3370714A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF FATTY ACIDIFICATION DISORDERS

Legal Events

Date Code Title Description
FG Grant or registration